Myriad Genetics Corporate Presentation

11/11/2015
Forward Looking Statements

Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based on management’s current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company’s annual reports on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company’s projections or forward-looking statements.
Our vision...

A trusted advisor transforming patients’ lives worldwide with pioneering molecular diagnostics

The Global Leader in Personalized Medicine
U.S. Healthcare System Remains Highly Inefficient

5% of patients represent 50% of healthcare costs*

*Agency for Healthcare Research and Quality

Drivers of Cost:
- Focus on treatment not prevention
- Late or incorrect diagnosis
- Undifferentiated treatments
- Trial and error approach to pharmaceuticals
Large Drivers of Inefficiencies Represent Blue Ocean Opportunities

S P E N D I N G
High
Moderate
Low

Low
Moderate
High

Autoimmune Disease
Neuroscience
Preventive Care
Urology
Dermatology
Oncology

“Blue Ocean”

Bubble size = healthcare spend
Myriad’s Mission Statement

Answering patients’ **four**
most pressing questions

Will I get a disease?
Do I have a disease?
Should I treat this disease?
How should I treat this disease?

In **six** medical specialties

- Oncology
- Preventive Care
- Urology
- Dermatology
- Autoimmune
- Neuroscience
Unmatched Competitive Advantages in Personalized Medicine

• Profitable R&D driven molecular diagnostic company
• Expertise in DNA, RNA, and proteins
• Strong research capabilities; extensive collaborations (>50 institutions and >20 pharma/bio companies)
• Broad regulatory experience (CLIA, FDA, CE mark)
• Deep physician relationships (>90,000 ordering physicians since inception)
• Extensive managed care contracts (>600)
• Reputation for best-in-class quality for high-complexity tests (>2 million performed)
Our Strategic Goals By 2020

- >10% Revenue Growth CAGR
- >30% Operating Margin
- 7 Products with Revenue >$50 Million
- International Revenue >10%

Goals By 2020
Our Strategic Imperatives to Achieve Our **FIVE**-Year Goals

- Transition & Expand the Hereditary Cancer Market
- Diversify the Portfolio
- Increase International Contribution
Our Strategic Imperatives to Achieve Our **FIVE**-Year Goals

Transition & Expand the Hereditary Cancer Market

Diversify the Portfolio

Increase International Contribution
Hereditary Cancer Market Remains Significant Untapped Opportunity

- ≈1 in 500 people have a mutation in a hereditary cancer gene
- ≈15M adults in United States qualify for hereditary cancer testing
- $30B TAM
- Less than 10% have been tested
- Deleterious mutations lead to up to a 7 fold risk of breast cancer and up to a 16 fold risk of colorectal cancer
- Cost effective interventional steps can reduce lifetime risk to below the general population risk

- National Cancer Institute; Surgery to Reduce Risk of Breast Cancer
- Risk of colorectal adenoma and carcinoma after colectomy for colorectal cancer in patients meeting Amsterdam criteria.
Hereditary Cancer Market Rapidly Transitioning to Higher Value Multi-Gene Panels

- myRisk™ Hereditary Cancer is a 25 gene panel
- All genes are clinically actionable; 19 have NCCN guidelines
- ≈80% of incoming samples currently ordered as myRisk
- Facilitates expanded indications with incremental $500M TAM
- Long-term managed care contracts establish pricing stability

Number of Deleterious Mutations Found

<table>
<thead>
<tr>
<th>Patients Who Meet Criteria For Hereditary Breast Cancer</th>
<th>Patients Who Meet Criteria For Hereditary Colon Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Single Gene Tests</td>
<td>myRisk Hereditary Cancer</td>
</tr>
</tbody>
</table>

96% Increase  108% Increase

* Based on data from 4,486 patients tested at Myriad Genetics
Hereditary Cancer Revenue Has Been More Durable Than Investors Anticipated

Share loss concentrated in the academic/genetic segment

- Medicare price reduction
- Higher Medicaid mix
- Small private payer reductions

Market Share
- Q1 FY16: 90%
- Q4 FY13: 94%

ASP
## Sustainable Competitive Advantages Expand in the Future

<table>
<thead>
<tr>
<th>Factor</th>
<th>Lab Accuracy</th>
<th>Variant Classification</th>
<th>Customer Support</th>
</tr>
</thead>
<tbody>
<tr>
<td>Myriad Advantages</td>
<td>• Requires perfection</td>
<td>• 20 years of research and &gt;$100M investment</td>
<td>• 11,000 oncologists and breast surgeons</td>
</tr>
<tr>
<td></td>
<td>• 85,000 bases analyzed</td>
<td>• 2 million patients tested</td>
<td>• 35,000 OBGYNs</td>
</tr>
<tr>
<td></td>
<td>• 856 distinct manufacturing steps</td>
<td>• 40,000 variant database that is rapidly expanding</td>
<td>• 375 person sales team</td>
</tr>
<tr>
<td></td>
<td>• 23 major technology platforms</td>
<td>• Avoid public databases that are fraught with errors</td>
<td>• 80 person clinical team</td>
</tr>
<tr>
<td></td>
<td>• 100 proprietary software applications</td>
<td>• Proprietary methods</td>
<td>• Tailored report developed with &gt;40,000 coding hours</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Extensive managed care contracts (&gt;600)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Industry leading turnaround time</td>
</tr>
</tbody>
</table>
Our Strategic Imperatives to Achieve Our FIVE-Year Goals

Transition & Expand the Hereditary Cancer Market
Diversify the Portfolio
Increase International Contribution
### 4in6 Pipeline Represents Two-Thirds of Opportunities Marketed or Under Development

<table>
<thead>
<tr>
<th></th>
<th>Risk?</th>
<th>Diagnosis?</th>
<th>Prognosis?</th>
<th>Therapy?</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Oncology</strong></td>
<td>✔</td>
<td></td>
<td>✔</td>
<td></td>
</tr>
<tr>
<td><strong>Preventive Care</strong></td>
<td>✔</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Urology</strong></td>
<td></td>
<td></td>
<td>✔</td>
<td></td>
</tr>
<tr>
<td><strong>Dermatology</strong></td>
<td>✔</td>
<td>✔</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Neuroscience</strong></td>
<td></td>
<td>✔</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Autoimmune</strong></td>
<td></td>
<td>✔</td>
<td>✔</td>
<td></td>
</tr>
</tbody>
</table>

- ✔: Currently Marketed
- ![Icon](image): Under Development
Industry Leading Pipeline Facilitates Long-Term Growth

Total Addressable Market (TAM)

<table>
<thead>
<tr>
<th>Stage 3</th>
<th>Stage 2</th>
<th>Stage 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>REIMBURSEMENT</td>
<td>VALIDATION</td>
<td>DISCOVERY</td>
</tr>
<tr>
<td>• myRisk Hereditary Cancer</td>
<td>• myPath® Melanoma</td>
<td>• myPath® Bipolar</td>
</tr>
<tr>
<td>• Vectra DA®</td>
<td>• myChoice™ HRD (Platinum)²</td>
<td>• myPath® Pancreatic Cancer</td>
</tr>
<tr>
<td>• Prolaris®</td>
<td>• myChoice HRD™ (PARP)³</td>
<td>• myPath® Psoriatic Arthritis</td>
</tr>
<tr>
<td>• EndoPredict®</td>
<td>• myPlan® Lung Cancer</td>
<td>• myPath® Prostate Cancer</td>
</tr>
<tr>
<td>• BRACAnalysis CDx™¹</td>
<td>• myPlan® Renal Cancer</td>
<td>• myPath® Endometriosis</td>
</tr>
<tr>
<td>• Tumor BRACAnalysis CDx®</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

¹ Ovarian Cancer, Breast Cancer, Pancreatic Cancer
² Triple Negative Breast Cancer, HER2- Breast Cancer
³ Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Metastatic Prostate Cancer
Vectra DA
 Vectra DA Fills a Substantial Unmet Clinical Need

- Historical methodology for assessing rheumatoid arthritis disease activity has been subjective physician joint assessment (DAS 28)
- Unable to detect changes in disease activity before irreversible bone damage
- Vectra DA is a 12 protein biomarker test that provides an objective assessment of disease activity
- Multiple studies show the test’s ability to predict radiographic progression (gold standard endpoint for RA)
Vectra DA Supported by Robust Clinical Data

- 17 clinical studies with >3,000 patients
- Indicated for 3 million RA patients globally; represents a $3B TAM
- U.S. Medicare reimbursement alone supports $600M market
- 40% of U.S. rheumatologists have ordered
- FY2015 revenue $43M

% Radiographic Progression*

<table>
<thead>
<tr>
<th>Patient Group</th>
<th>Relative Risk</th>
<th>p = 0.008</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low (&lt;30)</td>
<td>0%</td>
<td></td>
</tr>
<tr>
<td>Moderate (30-44)</td>
<td>7x</td>
<td></td>
</tr>
<tr>
<td>High (&gt;44)</td>
<td>25%</td>
<td></td>
</tr>
</tbody>
</table>

* % Patients with ΔSHS >5 BL to year 1

Prolaris
Most Prostate Cancer Patients Inappropriately Treated

**AUA Low-Risk Patients**
- Most low-risk patients have a low risk of prostate-specific mortality
- Yet the vast majority are treated upfront

**AUA Intermediate Risk Patients**
- More than half will experience biochemical recurrence with single-modality treatment alone

**AUA High-Risk Patients**
- Yet the majority do not receive multi-modality treatment

**RESULTS WITHOUT IMPROVED TOOLS**
- Overtreatment Problem
- Undertreatment Problem
Prolaris Supported by Robust Clinical Data

- 10 clinical studies with >4,000 patients
- Indicated for 500,000 global patients per year with a TAM of $1.5B
- Medicare reimbursement currently supports $200M U.S. market
- Signed first commercial payer (Tufts Health Plan)
- Over 20% of urologists have ordered the test
- 119% YoY volume growth in 1Q16

Active Surveillance Threshold

3% Mortality    20% Mortality

Low Prolaris Combined Score
High Prolaris Combined Score

Pathology Recommends Active Surveillance
Pathology Does Not Recommend Active Surveillance

*Cuzick 2015 AUA
Companion Diagnostics for DNA Damaging Agents
Requirement for Diagnostic to Detect DNA Repair Pathway Defect

Normal Cell

DNA Repair

Cell Survives

Tumor Cell

Compromised DNA Repair

Cell Proliferates

Principle of Synthetic Lethality

Induce DNA damage and/or block alternative repair pathways in tumor cells with compromised DNA repair mechanisms

Cell Dies

Requirement:
Diagnostic to detect tumors that have lost the ability to repair DNA

1.4M Patients/Year Could Benefit = $6B TAM
<table>
<thead>
<tr>
<th></th>
<th>BRACAnalysis CDx™</th>
<th>Tumor BRACAnalysis CDx™</th>
<th>myChoice HRD™</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>% Positive</strong></td>
<td>15%</td>
<td>22%</td>
<td>48%</td>
</tr>
<tr>
<td>(Ovarian)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Sample</strong></td>
<td>Blood</td>
<td>Tumor</td>
<td></td>
</tr>
<tr>
<td><strong>Biomarkers</strong></td>
<td>BRCA1&amp;2</td>
<td>Tumor BRCA1&amp;2</td>
<td></td>
</tr>
<tr>
<td><strong>Intellectual</strong></td>
<td>Database, process, bioinformatics</td>
<td>Database, process, bioinformatics</td>
<td><strong>IP on three proprietary technologies (LOH, TAI, &amp; LST)</strong></td>
</tr>
<tr>
<td><strong>Property</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Currently</strong></td>
<td>Yes, FDA approved in U.S. for use with Lynparza™</td>
<td>Yes, marketed in Europe only</td>
<td></td>
</tr>
<tr>
<td><strong>Marketed</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Partners</strong></td>
<td>AstraZeneca, Medivation, TESARO, AbbVie</td>
<td>AstraZeneca, Medivation, TESARO, AbbVie</td>
<td>Medivation, TESARO, Platinum</td>
</tr>
</tbody>
</table>
Extensive Collaborations With >22 Clinical Studies

Global Market = 1.4M patients or $6.0b*

*Includes U.S., Canada and EU6

myPath Melanoma
Traditional Melanoma Diagnosis is Highly Subjective

15% to 47% discordance in peer reviewed literature

<table>
<thead>
<tr>
<th>STUDY</th>
<th>N</th>
<th>DISCORDANCE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cerroni et al.</td>
<td>57</td>
<td>47%</td>
</tr>
<tr>
<td>Hawryluk et al.</td>
<td>478</td>
<td>35%</td>
</tr>
<tr>
<td>Piepkorn et al.</td>
<td>149</td>
<td>46%</td>
</tr>
<tr>
<td>Gerami et al.</td>
<td>24</td>
<td>30%</td>
</tr>
<tr>
<td>Veenhuizen et al.</td>
<td>1,069</td>
<td>15%</td>
</tr>
<tr>
<td>Shoo et al.</td>
<td>392</td>
<td>15%</td>
</tr>
<tr>
<td>Lodha et al.</td>
<td>178</td>
<td>25%</td>
</tr>
<tr>
<td>Farmer et al.</td>
<td>37</td>
<td>35%</td>
</tr>
<tr>
<td><strong>Overall</strong></td>
<td>2,384</td>
<td><strong>31%</strong></td>
</tr>
</tbody>
</table>
myPath Melanoma Beginning Reimbursement Process

- 5 clinical studies with ≈2,000 patients
- Indicated for 400,000 global patients per year with a TAM of $600M
- 22% of dermatopathologists in the U.S. have ordered the test
- 138% volume growth in FY15

*Clinical Validation of a Gene Expression Signature That Differentiates Benign Nevi From Malignant Melanoma*
Our Strategic Imperatives to Achieve Our **FIVE**-Year Goals

- Transition & Expand the Hereditary Cancer Market
- Diversify the Portfolio
- Increase International Contribution
Total Available Market (TAM) in 10 Major International Markets > U.S.

% of Worldwide Medical Technology Consumption

- EU6 + Canada Near Term Opportunity: 50% of U.S. Market
- Long-Term Opportunity: > 70% of U.S. Market

Source: European Federation for Pharmaceutical Industry IFPMA Facts & Figures 2012
**Refined Strategy to Reflect Unique International Market**

<table>
<thead>
<tr>
<th>COUNTRIES</th>
<th>REFERENCE TESTS</th>
<th>KITS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Near-Term Growth:</td>
<td>DNA (multiple platforms):</td>
<td>RNA (platform partner):</td>
</tr>
<tr>
<td>EU6 + Canada</td>
<td>Companion Diagnostics</td>
<td>• EndoPredict</td>
</tr>
<tr>
<td>Long-Term Growth:</td>
<td></td>
<td>• Prolaris</td>
</tr>
<tr>
<td>Japan, China, and Brazil</td>
<td></td>
<td>• myPlan Lung</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• myPath Melanoma</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• myPlan Renal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Protein (platform partner):</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Vectra DA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• myPath Bipolar</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• myPath Pancreatic</td>
</tr>
</tbody>
</table>
Financial Outlook
Five Year Plan Anticipates Greater Than 10% Revenue CAGR Over Next Five Years

- HEREDITARY CANCER
- COMPANION DX
- VECTRA DA
- PROLARIS
- MYPATH MELANOMA
- PHARMA & CLIN SERVICES/OTHER

Less than 50% of revenue from hereditary cancer

Market Penetration 9%
Increased Profitability In Pipeline Products Supports >30% Operating Margins

- FY15: (6.0%)
- Hereditary Cancer: 7.0%
- Autoimmune: 3.0%
- Urology: 1.0%
- Dermatology: 2.0%
- International: 2.0%
- FY20: 30%
## Capital Deployment Strategy

<table>
<thead>
<tr>
<th>CAPITAL ALLOCATION PRIORITY</th>
<th>CAPITAL DEPLOYMENT SINCE JUNE 2010</th>
<th>GOAL</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>R&amp;D</strong></td>
<td>9% of revenue</td>
<td>8% to 10% of revenue</td>
</tr>
</tbody>
</table>
| **M&A**                     | ≈ $340M 43% of FCF                 | • Use cash on hand to fund smaller deals (< $100M)  
• Use cash and leverage to fund larger deals ($100M-$600M)  
• Use equity to fund strategic deals (beyond borrowing capacity) |
| **Share Repurchase**        | >$1B 127% of FCF                   | • Target 100% of FCF  
• Reduce share repurchases based upon M&A visibility  
• Maintain cash at $100M to $200M |
| **Dividend**                | None                               | No plans for dividend given more attractive uses of capital |
Worldwide Leader in Personalized Medicine

• We are entering the golden age for personalized medicine
• We are the pioneers of “research-based” and “education-centric” business modeling for diagnostics
• No company is better positioned to lead this revolution in healthcare than Myriad